ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Portland, OR

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Esophageal Cancer
Prostatic Cancer

Adenocarcinoma trials near Portland, OR, USA:

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignatur...

Enrolling
Endometrial Adenocarcinoma
Urothelial Carcinoma
Diagnostic Test: OncoSignature
Drug: ACR-368

Phase 1, Phase 2

Acrivon Therapeutics

Portland, Oregon, United States and 66 other locations

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma...

Enrolling
Esophageal Cancer
Gastric Cancer
Biological: LB1908

Phase 1

Legend Biotech

Portland, Oregon, United States and 3 other locations

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating re...

Active, not recruiting
Rectal Adenocarcinoma
Procedure: Tumor specific mesorectal excision
Drug: LY2157299

Phase 2

Providence Health & Services
Providence Health & Services

Portland, Oregon, United States

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Active, not recruiting
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Domvanalimab
Drug: Zimberelimab

Phase 3

Arcus Biosciences
Arcus Biosciences

Portland, Oregon, United States and 203 other locations

Locations recently updated

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)

after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...

Enrolling
Non-small Cell Lung Cancer
Drug: Pemetrexed
Drug: Rilvegostomig

Phase 3

AstraZeneca
AstraZeneca

Portland, Oregon, United States and 214 other locations

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancre...

Enrolling
Unresectable Pancreatic Ductal Adenocarcinoma
Resectable Pancreatic Ductal Adenocarcinoma
Biological: Tremelimumab
Drug: Azenosertib

Early Phase 1

OHSU Knight Cancer Institute
OHSU Knight Cancer Institute

Portland, Oregon, United States

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastroesophageal Junction Cancer
Gastric Cancer
Drug: AZD0901
Drug: Docetaxel

Phase 3

AstraZeneca
AstraZeneca

Portland, Oregon, United States and 176 other locations

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why was this study being done? SPOTLIGHT was a new clinical ...

Active, not recruiting
Metastatic Gastric Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Drug: folinic acid
Drug: zolbetuximab

Phase 3

Astellas
Astellas

Portland, Oregon, United States and 219 other locations

A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C\*08:02-restricted T cell receptor (TCR), tar...

Enrolling
Pancreatic Ductal Adenocarcinoma
Endometrial Cancer
Biological: NT-112: Autologous, engineered T Cells targeting KRAS G12D

Phase 1

AstraZeneca
AstraZeneca

Portland, Oregon, United States and 11 other locations

Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC (ESOGUARDBE2)

Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plu...

Enrolling
Esophageal Adenocarcinoma
Barretts Esophagus With Dysplasia
Diagnostic Test: Esophagogastroduodenoscopy
Device: EsoGuard (lab assay)
Lucid Diagnostics

Portland, Oregon, United States and 37 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems